The antiviral, molnupiravir, does not reduce coronavirus hospital admissions or deaths in vaccinated people at high risk, new research suggests.
But the treatment was associated with a shorter recovery time, by four days, and reduced viral load.
People who received molnupiravir reported feeling better compared to those who received usual care, the study found.
Researchers suggest that while the drug could have some benefits in terms of symptom reduction, the cost of the drug may mean it is not the best choice for the general population, given the study findings.
But it may